Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 7/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17876462 | 0.93 | CYP2C9 (0.54) | CYP2C9CYP2C19CYP3A4ALDH1A1MAPT | |
| SCHEMBL17876461 | 0.93 | CYP2C9 (0.54) | CYP2C9CYP2C19CYP3A4ALDH1A1MAPT | |
| SCHEMBL17876708 | 0.92 | CYP2C9 (0.69) | CYP2C9CYP2C19CYP3A4ALDH1A1LMNA | |
| SCHEMBL12295712 | 0.92 | CYP2C9 (0.65) | CYP2C9CYP2C19CYP3A4ALDH1A1MAPT | |
| SCHEMBL17876464 | 0.91 | CYP2C9 (0.61) | CYP2C9CYP2C19CYP3A4LMNATHRB | |
| SCHEMBL14761171 | 0.91 | CYP2C9 (0.64) | CYP2C9CYP2C19CYP3A4ALDH1A1MAPT | |
| SCHEMBL17876463 | 0.90 | CYP2C9 (0.53) | CYP2C9CYP2C19CYP3A4THRB | |
| SCHEMBL16447380 | 0.90 | CYP2C9 (0.68) | CYP2C9CYP2C19CYP3A4ALDH1A1LMNA | |
| SCHEMBL17876458 | 0.89 | THRB (0.57) | CYP2C9CYP2C19CYP3A4ALDH1A1LMNA | |
| SCHEMBL12295465 | 0.89 | CYP2C9 (0.62) | CYP2C9CYP2C19CYP3A4LMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3027615-B1 | ANTI-INFECTIVE COMPOUNDS | PASTEUR INSTITUT KOREA (KR) | 2021-07-21 | — | — | EP | disclosed |
| US-20160185774-A1 | Anti-Infective Compounds | INSTITUT PASTEUR KOREA (KR) | 2016-06-30 | — | — | US | disclosed |
| US-20160185774-A1 | Anti-Infective Compounds | INSTITUT PASTEUR KOREA (KR) | 2016-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160185774-A1 | Anti-Infective Compounds | RABGGTB, ELANE, SERPINB1 | CYP2C9 4235/4885CYP2C19 4181/4885CYP3A4 2915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.